Cytovance Biologics

Cytovance Biologics is a private, revenue-generating CDMO focused on the outsourced development and manufacturing of biologics and antibodies. The company serves biotechnology and pharmaceutical clients, offering a suite of services from early-stage process development to large-scale commercial production. Its business model is based on providing essential manufacturing capacity and expertise to innovators, positioning it within the high-growth biologics CDMO sector. As a service provider, its pipeline is defined by its clients' programs, which span a wide range of therapeutic areas.

Dual-platform CDMO offering microbial (E. coli, P. pastoris) and mammalian (CHO) cell-based development and cGMP manufacturing services for biologics and antibodies.

Cytovance operates in the highly competitive biologics CDMO sector, competing against large global players (e.g., Lonza, Catalent, Samsung Biologics) and numerous niche specialists. Its differentiation lies in its mid-size, client-focused approach and dual microbial/mammalian platform capabilities within the North American market.